← SynDRA
TOZASERTIB
SynDRA canonical compound SYN0009119 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | AURKB |
|---|
| Mechanism of action | Aurora kinase inhibitor |
|---|
All known targets
- AURKA
- AURKB
- AURKC
- ABL1
- BCR
- FLT3
- JAK2
- LCK
- DDR2
Mechanisms of action (all sources)
- JAK inhibitor
- FLT3 INHIBITOR
- Abl kinase inhibitor
- aurora kinase inhibitor
- AURKB INHIBITOR
- Serine/threonine-protein kinase Aurora inhibitor
- AURKC INHIBITOR
- AURKA INHIBITOR
- Bcr-Abl kinase inhibitor
- LCK INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- FLT4
- FYN
- GAK
- PTK2B
- GRK4
- PRP4K
- HCK
- PRKCQ
- HUNK
- IGF1R
- IKBKE
- INSR
- INSRR
- IRAK3
- IRAK4
- ITK
- JAK1
- JAK3
- KDR
- KIT
- LATS1
- LATS2
- LIMK1
- LIMK2
- LRRK2
- LTK
- LYN
- MAP2K1
- FRK
- FLT1
- MAP2K5
- FGR
- ROS1
- RIPK4
- EGFR
- RIPK1
- EIF2AK4
- RIOK3
- EPHA1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- AAPK1
- MP2K2
- M3K4
- M3K9
- M4K2
- M4K3
- M4K4
- M4K5
- MDM2
- MDM4
- MK10
- MP2K1
- MP2K6
- M3K12
- MRGPRX1
- NNMT
- NSD2
- PGFRA
- PGFRB
- PI42B
- PI51A
- PNMT
- VGFR1
- VGFR2
- M3K20
- M3K11
- AAPK2
- GEMI
- ALAT2
- BARD1
- BRCA1
- COMT
- CSK21
- CSK22
- CYP19A1
- E2AK4
- EPAS1
- GAMT
- GNMT
- M3K10
Cross-references
Synonyms
- MK-0457
- VX-680
- VX 680
- VX6
- L-001281814
- MK-045
- Tozasertib (USAN)
- VX-68
- MK-0457, Tozasertib, VX680, VX-680
- N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide
- N-(4-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide
- Cyclopropanecarboxylic acid N-(4-((4-(4-methylpiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-yl)sulfanyl)phenyl)amide
- Cyclopropane carboxylic acid{4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidin-2-ylsulphanyl]-phenyl}-amide
- Cyclopropanecarboxylic Acid {4-[4-(4-Methyl-Piperazin-1-Yl)-6-(5-Methyl-2h-Pyrazol-3-Ylamino)-Pyrimidin-2-Ylsulfanyl]-Phenyl}-Amide
- MK 0457
- VX680
- VX-680 (MK-0457,Tozasertib)
- Tozasertib (VX-680)
- Tozasertib [USAN]
- CHEMBL572878
- N-[4-({4-[(3-methyl-1H-pyrazol-5-yl)amino]-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide
- N-[4-[[4-(4-Methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide
- 234335M86K
- Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-
- Cyclopropanecarboxamide,N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-
- N-(4-((4-((5-methyl-1H-pyrazol-3-yl)amino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl)thio)phenyl)cyclopropanecarboxamide
- (N-[4({4-(4-methylpiperazin-1-yl)-6-[(3-methyl-1H-pyrazol-5 -yl)amino]pyrimidin-2-yl}thio)phenyl]cyclopropanecarboxamide)
- Cyclopropanecarboxamide, N-(4-((4-(4-methyl-1-piperazinyl)-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)thio)phenyl)-
- N-(4-((4-(4-Methylpiperazin-1-yl)-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)sulfanyl)phenyl)cyclopropanecarboxamide
- Tozasertib [USAN:INN]
- UNII-234335M86K
- N-[4-({4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide
- VE 465
- VX-680 (MK-0457, Tozasertib)
- Kinome_3803
- 2f4j
- TOZASERTIB [INN]
- Tozasertib (MK-0457)
Look up TOZASERTIB in the interactive SynDRA portal →